IFNA1 and relapsing-remitting multiple sclerosis: The lower proportion of CD3−CD56+CD16+ NK and CD3+CD56+ cells in the peripheral blood of IFN-treated patients with RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder.